{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T13:23:21Z","timestamp":1787491401176,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001960","name":"American Society for Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001960","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Stereotactic body radiotherapy (SBRT) is becoming increasingly used in treating localized prostate cancer (PCa), with evidence showing similar toxicity and efficacy profiles when compared with longer courses of definitive radiation. Magnetic resonance imaging (MRI)-guided radiotherapy has multiple potential advantages over standard computed tomography (CT)-guided radiotherapy, including enhanced prostate visualization (abrogating the need for fiducials and MRI fusion), enhanced identification of the urethra, the ability to track the prostate in real-time, and the capacity to perform online adaptive planning. However, it is unknown whether these potential advantages translate into improved outcomes. This phase III randomized superiority trial is designed to prospectively evaluate whether toxicity is lower after MRI-guided versus CT-guided SBRT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Three hundred men with localized PCa will be randomized in a 1:1 ratio to SBRT using CT or MRI guidance. Randomization will be stratified by baseline International Prostate Symptom Score (IPSS) (\u226415 or\u2009&gt;\u200915) and prostate gland volume (\u226450\u2009cc or\u2009&gt;\u200950\u2009cc). Five fractions of 8\u2009Gy will be delivered to the prostate over the course of fourteen days, with or without hormonal therapy and elective nodal radiotherapy (to a dose of 5\u2009Gy per fraction) as per the investigator\u2019s discretion. The primary endpoint is the incidence of physician-reported acute grade\u2009\u2265\u20092 genitourinary (GU) toxicity (during the first 90\u2009days after SBRT), as assessed by the CTCAE version 4.03 scale. Secondary clinical endpoints include incidence of acute grade\u2009\u2265\u20092 gastrointestinal (GI) toxicity, 5-year cumulative incidences of physician-reported late grade\u2009\u2265\u20092 GU and GI toxicity, temporal changes in patient-reported quality of life (QOL) outcomes, 5-year biochemical recurrence-free survival and the proportion of fractions of MRI-guided SBRT in which online adaptive radiotherapy is used.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>The MIRAGE trial is the first randomized trial comparing MRI-guided with standard CT-guided SBRT for localized PCa. The primary hypothesis is that MRI-guided SBRT will lead to an improvement in the cumulative incidence of acute grade\u2009\u2265\u20092 GU toxicity when compared to CT-guided SBRT. The pragmatic superiority design focused on an acute toxicity endpoint will allow an early comparison of the two technologies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">Clinicaltrials.gov<\/jats:ext-link> identifier: NCT04384770. Date of registration: May 12, 2020.<\/jats:p>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04384770\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04384770<\/jats:ext-link><\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Protocol version<\/jats:title>\n                <jats:p>Version 2.1, Aug 28, 2020.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08281-x","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T12:03:50Z","timestamp":1620734630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial"],"prefix":"10.1186","volume":"21","author":[{"given":"Ting Martin","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Vincent","family":"Basehart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nzhde","family":"Agazaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Nickols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minsong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"issue":"9856","key":"8281_CR1","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/S0140-6736(12)60919-2","volume":"380","author":"I Soerjomataram","year":"2012","unstructured":"Soerjomataram I, Lortet-Tieulent J, Parkin DM, Ferlay J, Mathers C, Forman D, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet. 2012;380(9856):1840\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(12)60919-2.","journal-title":"Lancet"},{"issue":"1","key":"8281_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin"},{"key":"8281_CR3","unstructured":"Network, N.C.C. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. 2019 1\/25\/2019 11\/30\/2015]; Version I.2019:[Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"issue":"11","key":"8281_CR4","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","volume":"20","author":"DH Brand","year":"2019","unstructured":"Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019;20(11):1531\u201343. https:\/\/doi.org\/10.1016\/S1470-2045(19)30569-8.","journal-title":"Lancet Oncol"},{"issue":"2","key":"8281_CR5","doi-asserted-by":"publisher","first-page":"e188006","DOI":"10.1001\/jamanetworkopen.2018.8006","volume":"2","author":"AU Kishan","year":"2019","unstructured":"Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate Cancer. JAMA Netw Open. 2019;2(2):e188006. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.8006.","journal-title":"JAMA Netw Open"},{"issue":"10196","key":"8281_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(19)31131-6.","journal-title":"Lancet"},{"issue":"10","key":"8281_CR7","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1046\/j.1525-1497.2000.90842.x","volume":"15","author":"ES Holmboe","year":"2000","unstructured":"Holmboe ES, Concato J. Treatment decisions for localized prostate cancer: asking men what's important. J Gen Intern Med. 2000;15(10):694\u2013701. https:\/\/doi.org\/10.1046\/j.1525-1497.2000.90842.x.","journal-title":"J Gen Intern Med"},{"issue":"12","key":"8281_CR8","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa074311","volume":"358","author":"MG Sanda","year":"2008","unstructured":"Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250\u201361. https:\/\/doi.org\/10.1056\/NEJMoa074311.","journal-title":"N Engl J Med"},{"issue":"11","key":"8281_CR9","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1111\/j.1464-410X.2010.09833.x","volume":"107","author":"CN Anandadas","year":"2011","unstructured":"Anandadas CN, Clarke NW, Davidson SE, O\u2019Reilly PH, Logue JP, Gilmore L, et al. Early prostate cancer--which treatment do men prefer and why? BJU Int. 2011;107(11):1762\u20138. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09833.x.","journal-title":"BJU Int"},{"issue":"2","key":"8281_CR10","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jama.2019.20675","volume":"323","author":"KE Hoffman","year":"2020","unstructured":"Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA, et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate Cancer. Jama. 2020;323(2):149\u201363. https:\/\/doi.org\/10.1001\/jama.2019.20675.","journal-title":"Jama"},{"issue":"11","key":"8281_CR11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jama.2017.1652","volume":"317","author":"RC Chen","year":"2017","unstructured":"Chen RC, Basak R, Meyer AM, Kuo TM, Carpenter WR, Agans RP, et al. Association between choice of radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient-reported quality of life among men with localized prostate Cancer. Jama. 2017;317(11):1141\u201350. https:\/\/doi.org\/10.1001\/jama.2017.1652.","journal-title":"Jama"},{"issue":"15","key":"8281_CR12","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","volume":"375","author":"JL Donovan","year":"2016","unstructured":"Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate Cancer. N Engl J Med. 2016;375(15):1425\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1606221.","journal-title":"N Engl J Med"},{"issue":"3","key":"8281_CR13","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.eururo.2018.12.003","volume":"75","author":"R Matta","year":"2019","unstructured":"Matta R, Chapple CR, Fisch M, Heidenreich A, Herschorn S, Kodama RT, et al. Pelvic complications after prostate Cancer radiation therapy and their management: an international collaborative narrative review. Eur Urol. 2019;75(3):464\u201376. https:\/\/doi.org\/10.1016\/j.eururo.2018.12.003.","journal-title":"Eur Urol"},{"issue":"2","key":"8281_CR14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","volume":"102","author":"RM Meier","year":"2018","unstructured":"Meier RM, Bloch DA, Cotrutz C, Beckman AC, Henning GT, Woodhouse SA, et al. Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate Cancer: survival and toxicity endpoints. Int J Radiat Oncol Biol Phys. 2018;102(2):296\u2013303. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.05.040.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"8281_CR15","doi-asserted-by":"publisher","first-page":"e180039","DOI":"10.1001\/jamaoncol.2018.0039","volume":"14","author":"JM Michalski","year":"2018","unstructured":"Michalski JM, et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate Cancer: the NRG oncology RTOG 0126 randomized clinical trial. JAMA Oncol. 2018;14(4):e180039.","journal-title":"JAMA Oncol"},{"issue":"3","key":"8281_CR16","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.ijrobp.2012.05.023","volume":"85","author":"DE Spratt","year":"2013","unstructured":"Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85(3):686\u201392. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.05.023.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"8281_CR17","first-page":"6373","volume":"19","author":"N Ohri","year":"2012","unstructured":"Ohri N, Dicker AP, Showalter TN. Late toxicity rates following definitive radiotherapy for prostate cancer. Can J Urol. 2012;19(4):6373\u201380.","journal-title":"Can J Urol"},{"issue":"9","key":"8281_CR18","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.clon.2017.03.006","volume":"29","author":"K Byrne","year":"2017","unstructured":"Byrne K, Hruby G, Kneebone A, Whalley D, Guo L, McCloud P, et al. Late genitourinary toxicity outcomes in 300 prostate Cancer patients treated with dose-escalated image-guided intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol). 2017;29(9):617\u201325. https:\/\/doi.org\/10.1016\/j.clon.2017.03.006.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"6","key":"8281_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0039","volume":"4","author":"JM Michalski","year":"2018","unstructured":"Michalski JM, Moughan J, Purdy J, Bosch W, Bruner DW, Bahary JP, et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate Cancer: the NRG oncology RTOG 0126 randomized clinical trial. JAMA Oncol. 2018;4(6):e180039. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0039.","journal-title":"JAMA Oncol"},{"issue":"1","key":"8281_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.juro.2012.08.091","volume":"189","author":"S Kim","year":"2013","unstructured":"Kim S, Moore DF, Shih W, Lin Y, Li H, Shao YH, et al. Severe genitourinary toxicity following radiation therapy for prostate cancer--how long does it last? J Urol. 2013;189(1):116\u201321. https:\/\/doi.org\/10.1016\/j.juro.2012.08.091.","journal-title":"J Urol"},{"key":"8281_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.radonc.2019.11.017","volume":"144","author":"Y Alayed","year":"2020","unstructured":"Alayed Y, Davidson M, Quon H, Cheung P, Chu W, Chung HT, et al. Dosimetric predictors of toxicity and quality of life following prostate stereotactic ablative radiotherapy. Radiother Oncol. 2020;144:135\u201340. https:\/\/doi.org\/10.1016\/j.radonc.2019.11.017.","journal-title":"Radiother Oncol"},{"issue":"3","key":"8281_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/acm2.12529","volume":"20","author":"AU Pathmanathan","year":"2019","unstructured":"Pathmanathan AU, Schmidt MA, Brand DH, Kousi E, As NJ, Tree AC. Improving fiducial and prostate capsule visualization for radiotherapy planning using MRI. J Appl Clin Med Phys. 2019;20(3):27\u201336. https:\/\/doi.org\/10.1002\/acm2.12529.","journal-title":"J Appl Clin Med Phys"},{"issue":"2","key":"8281_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ijrobp.2017.10.020","volume":"100","author":"AU Pathmanathan","year":"2018","unstructured":"Pathmanathan AU, van As NJ, Kerkmeijer LGW, Christodouleas J, Lawton CAF, Vesprini D, et al. Magnetic resonance imaging-guided adaptive radiation therapy: a \"game changer\" for prostate treatment? Int J Radiat Oncol Biol Phys. 2018;100(2):361\u201373. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.10.020.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"8281_CR24","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.ijrobp.2017.04.023","volume":"99","author":"S Lim-Reinders","year":"2017","unstructured":"Lim-Reinders S, Keller BM, al-Ward S, Sahgal A, Kim A. Online adaptive radiation therapy. Int J Radiat Oncol Biol Phys. 2017;99(4):994\u20131003. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.04.023.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"8281_CR25","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.ijrobp.2019.08.007","volume":"105","author":"AME Bruynzeel","year":"2019","unstructured":"Bruynzeel AME, Tetar SU, Oei SS, Senan S, Haasbeek CJA, Spoelstra FOB, et al. A prospective single-arm phase 2 study of stereotactic magnetic resonance guided adaptive radiation therapy for prostate Cancer: early toxicity results. Int J Radiat Oncol Biol Phys. 2019;105(5):1086\u201394. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.08.007.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"8281_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","volume":"85","author":"TA Skolarus","year":"2015","unstructured":"Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, et al. Minimally important difference for the expanded prostate Cancer index composite short form. Urology. 2015;85(1):101\u20135. https:\/\/doi.org\/10.1016\/j.urology.2014.08.044.","journal-title":"Urology"},{"issue":"1068","key":"8281_CR27","doi-asserted-by":"publisher","first-page":"20160296","DOI":"10.1259\/bjr.20160296","volume":"89","author":"AG O'Neill","year":"2016","unstructured":"O'Neill AG, et al. Fiducial marker guided prostate radiotherapy: a review. Br J Radiol. 2016;89(1068):20160296. https:\/\/doi.org\/10.1259\/bjr.20160296.","journal-title":"Br J Radiol"},{"key":"8281_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3389\/fonc.2020.00539","volume":"10","author":"R Levin-Epstein","year":"2020","unstructured":"Levin-Epstein R, Qiao-Guan G, Juarez JE, Shen Z, Steinberg ML, Ruan D, et al. Clinical assessment of prostate displacement and planning target volume margins for stereotactic body radiotherapy of prostate Cancer. Front Oncol. 2020;10:539. https:\/\/doi.org\/10.3389\/fonc.2020.00539.","journal-title":"Front Oncol"},{"issue":"2","key":"8281_CR29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ijrobp.2008.08.002","volume":"74","author":"CA Lawton","year":"2009","unstructured":"Lawton CA, et al. RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74(2):383\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.08.002.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"8281_CR30","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate Cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1702900.","journal-title":"N Engl J Med"},{"issue":"5","key":"8281_CR31","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.urology.2010.01.027","volume":"76","author":"KM Szymanski","year":"2010","unstructured":"Szymanski KM, Wei JT, Dunn RL, Sanda MG. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology. 2010;76(5):1245\u201350. https:\/\/doi.org\/10.1016\/j.urology.2010.01.027.","journal-title":"Urology"},{"issue":"5","key":"8281_CR32","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","volume":"148","author":"MJ Barry","year":"1992","unstructured":"Barry MJ, Fowler FJ, O\u2019Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American urological association symptom index for benign prostatic hyperplasia. The measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549\u201357; discussion 1564. https:\/\/doi.org\/10.1016\/S0022-5347(17)36966-5.","journal-title":"J Urol"},{"issue":"6","key":"8281_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/sj.ijir.3900472","volume":"11","author":"RC Rosen","year":"1999","unstructured":"Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pe\u00f1a BM. Development and evaluation of an abridged, 5-item version of the international index of erectile function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11(6):319\u201326. https:\/\/doi.org\/10.1038\/sj.ijir.3900472.","journal-title":"Int J Impot Res"},{"issue":"1","key":"8281_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.urology.2008.03.036","volume":"74","author":"FJ Bianco Jr","year":"2009","unstructured":"Bianco FJ Jr, McHone BR, Wagner K, King A, Burgess J, Patierno S, et al. Prevalence of erectile dysfunction in men screened for prostate cancer. Urology. 2009;74(1):89\u201393. https:\/\/doi.org\/10.1016\/j.urology.2008.03.036.","journal-title":"Urology"},{"issue":"9","key":"8281_CR35","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1002\/cam4.2966","volume":"9","author":"T Zilli","year":"2020","unstructured":"Zilli T, Jorcano S, Bral S, Rubio C, Bruynzeel AME, Oliveira A, et al. Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results. Cancer Med. 2020;9(9):3097\u2013106. https:\/\/doi.org\/10.1002\/cam4.2966.","journal-title":"Cancer Med"},{"issue":"1","key":"8281_CR36","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s13063-017-2168-0","volume":"18","author":"EAM Neugebauer","year":"2017","unstructured":"Neugebauer EAM, Rath A, Antoine SL, Eikermann M, Seidel D, Koenen C, et al. Specific barriers to the conduct of randomised clinical trials on medical devices. Trials. 2017;18(1):427. https:\/\/doi.org\/10.1186\/s13063-017-2168-0.","journal-title":"Trials"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08281-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08281-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08281-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T12:04:28Z","timestamp":1620734668000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08281-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8281"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08281-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]},"assertion":[{"value":"29 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is approved by the Institutional Review Board (IRB) of the University of California Los Angeles (UCLA IRB #20\u2013000328). Subjects consent to participate after thorough discussion by signing of the IRB approved informed consent document. If any major amendments are made, subjects will be given the opportunity to re-consent after a full disclosure by the principal investigator and the clinical research coordinator.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript does not include details, images, or videos relating to an individual person.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests within the scope of the submitted work. Full disclosures include: AUK received honoraria from Varian Medical Systems, Inc. and ViewRay Inc., outside the scope of the submitted work. NN received research support from Janssen, Varian, and Bayer; stock options with GSI Inc. and ROAR; and consulting with GSI Inc., outside the scope of the submitted work. MC received speaker honorarium from ViewRay Inc. and Varian Medical System Inc., outside the scope of the submitted work. YY received speaker honorarium and consulting from Viewray inc., outside the scope of the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"538"}}